Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab for chronic rhinosinusitis with nasal polyps
2024-516815-26-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Itepekimab arm with Placebo arm (2 arms). Primary endpoints: Change from baseline in endoscopic Nasal Polyp Score (NPS) and Change from baseline in Nasal Congestion Score (NCS). Planned start May 2025; status: authorised.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-516815-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516815-26-00.